Foghorn Therapeutics Appoints Experienced Biotech Veteran Ryan Maynard as New CFO
FHTX sits 95% above its 52-week low of $2.945.
Summary
Foghorn Therapeutics has appointed Ryan D. Maynard, a seasoned biopharmaceutical executive with extensive experience in financial strategy and capital markets, as its new Chief Financial Officer.
Key Events · Executive and Board Changes · FHTX
-
New Chief Financial Officer Appointed
Ryan D. Maynard has been appointed as Chief Financial Officer, principal financial officer, and principal accounting officer, effective February 23, 2026.
-
Experienced Financial Leadership
Mr. Maynard brings over 25 years of executive experience from various public and private biopharmaceutical companies, including Cara Therapeutics and Rigel Pharmaceuticals, with a track record in financial strategy and capital raising.
-
Compensation Package Includes Equity Grant
His compensation includes an annual base salary of $510,000, a target annual bonus of 40%, a $90,000 signing bonus, and an option award to purchase 400,000 shares of common stock.
-
Interim CFO Steps Down
Jeff Sacher, the Interim Chief Financial Officer, will cease to serve in his interim roles following Mr. Maynard's appointment.
Analysis · FHTX · Life Sciences
The appointment of Ryan D. Maynard as Chief Financial Officer brings over 25 years of executive financial leadership experience in the biopharmaceutical sector to Foghorn Therapeutics. His background in capital markets execution and strategic transactions, including raising over $1 billion, is particularly valuable for a clinical-stage company that recently completed a $50 million financing round. This move strengthens the company's financial leadership as it advances its pipeline.
At the time of this filing, FHTX was trading at $5.73 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $335.7M. The 52-week trading range was $2.94 to $6.95. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.